This is general information, not an individual diagnosis or treatment plan. Outcomes vary between people.
What is PRP? Ovarian and intrauterine applications differ
Platelet-rich plasma, or PRP, is prepared from a person’s own blood using a centrifuge. Platelets carry signals involved in cell growth and repair. In fertility research, intrauterine PRP is introduced into the womb with the aim of influencing its lining, the endometrium. Intraovarian PRP involves injection into the ovaries with the aim of changing their response to stimulation. Findings for one route cannot establish benefit for the other. A thin endometrium, diminished ovarian reserve and previous unsuccessful treatment are distinct clinical situations, each requiring its own assessment. Using someone’s own blood does not automatically make the preparation or procedure safe or necessary.
What are exosomes, and how do they differ from PRP or stem cells?
Exosomes are a type of small extracellular vesicle released by cells. They carry proteins and molecules such as RNA and participate in communication between cells. They are not themselves stem cells, and the term is not interchangeable with PRP. Researchers are investigating their relationship with the ovarian environment, inflammation and egg development. Laboratory and animal findings cannot establish pregnancy or healthy-birth benefits in people. Early human studies also exist, but products differ in their source, isolation methods and intended use. Simply describing a preparation as an exosome product does not demonstrate that its contents, effectiveness or safety have been adequately verified.
What do the evidence and safety information show?
ESHRE’s recommendations on reproductive add-ons advise against intrauterine and intraovarian PRP. The HFEA’s current assessment also highlights insufficient reliable evidence of a live-birth benefit in the relevant patient groups and potential safety concerns. In the PROVA randomized trial, ovarian PRP did not improve mature egg yield in the group of women with poor ovarian response studied. Early exosome research is of scientific interest, but a pilot study examining egg maturation cannot by itself establish improved pregnancy or live-birth outcomes. Changes in AMH, lining thickness or egg numbers are not the same as having a baby. Infection, bleeding and procedure-related tissue injury need consideration alongside product purity, sterility and uncertain long-term effects.
Questions to take to your consultation
Ask what evidence applies to your diagnosis, whether reliable comparative research measured live births, what harms and alternatives should be considered, and how the product’s source, quality controls and authorization are checked. Ask whether a proposed intervention is part of research and whether it could delay established care. A trial registration is not proof of effectiveness or authorization for routine use. The FDA states that there are no FDA-approved exosome products in the United States; this does not determine the authorization of a particular product or procedure in Türkiye. Begin with an assessment of age, ovarian reserve, sperm findings, uterine factors and previous treatment records. You can discuss your existing results and questions with Prof. Dr. Mehmet Çolakoğlu at his own practice in Konya or at A Life Hospital – Etimesgut in Ankara. Use the Preliminary Consultation and Contact Form to take the first step towards an informed plan for the child you hope for.
Frequently asked questions
Can PRP or exosomes rejuvenate the ovaries?
Adequate clinical evidence has not established that they rejuvenate ovaries, create a new egg reserve or reverse age-related changes. Such descriptions should not be interpreted as a guarantee.
Is PRP necessary after an unsuccessful IVF attempt?
No. All stages of the previous attempt and the assessment of both partners should be reviewed. An unsuccessful result alone does not establish a need for PRP or exosomes.
Does using my own blood make PRP risk-free?
No. Preparation and administration can carry risks such as infection, bleeding or tissue injury. Long-term safety information for pregnancy and children remains insufficient.
Does a rise in AMH or lining thickness prove treatment success?
No. A change in a hormone measurement or endometrial thickness does not by itself show an improved chance of live birth. Results require appropriate comparative studies and safety information.
Discuss your personal next step.
Prof. Dr. Mehmet Çolakoğlu sees patients at his own practice in Konya and at A Life Hospital - Etimesgut.
Consultation and Contact Explore publicationsSources and further reading
- HFEA · Platelet-rich plasma (PRP) ↗
- ESHRE · Good practice recommendations on add-ons in reproductive medicine ↗
- PROVA · Randomized controlled trial of intraovarian PRP ↗
- Autologous exosomes · Pilot study of oocyte maturation (2026) ↗
- FDA · Consumer information on stem cells and exosomes (United States) ↗
